An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments

Trial Profile

An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

At a glance

  • Drugs Olaratumab (Primary) ; Pembrolizumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 May 2018 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
    • 10 May 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
    • 20 Oct 2017 Planned End Date changed from 13 Feb 2020 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top